Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Orbital

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    42 result(s) found for: Orbital. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2011-001869-41 Sponsor Protocol Number: OKHN1005 Start Date*: 2011-08-24
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: An exploratory study of ranibizumab (Lucentis) for treatment of uveitic patients with refractory cystoid macular oedema. 'The LIMO study'
    Medical condition: Uveitic Macular Oedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10046851 Uveitis PT
    20.1 10015919 - Eye disorders 10058202 Cystoid macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002127-26 Sponsor Protocol Number: BAFFI_14 Start Date*: 2015-10-13
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: Randomized, single-blind, controlled study of the anti-BAFF antibody belimumab or methylprednisolone treatment in hyperthyroid Graves' disease (GD) and active orbitopathy (GO)
    Medical condition: GRAVES' ORBITOPATHY
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001158-33 Sponsor Protocol Number: OZR-2016-34 Start Date*: 2017-07-20
    Sponsor Name:The Rotterdam Eye Hospital
    Full Title: A pilot study towards a therapy with prednisolone encapsulated liposomes for the treatment of Graves’ Orbitopathy with reduced systemic steroid exposure
    Medical condition: Graves' Orbitopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020482-24 Sponsor Protocol Number: 1 Start Date*: 2014-10-23
    Sponsor Name:Department of Endocrinology, Sahlgrenska University Hospital
    Full Title: Ga-68-DOTATOC -PET in the management of pituitary tumours (PA) and Thyroid associated ophtalmopathy (TAO)
    Medical condition: In this trial with Ga-68 DOTATOC two groupd of patients will be investigated - patients with pituitary adenoma (PA) and patients with thyroid associateed ophtalmopathy (TAO). As the eye muscles and...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-007799-40 Sponsor Protocol Number: 2021/07 Start Date*: 2008-01-28
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Evaluation of intralesional administration of rituximab for treatment of orbital lymphoma
    Medical condition: orbital lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003899 B-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000641-41 Sponsor Protocol Number: 2021-000641-41 Start Date*: 2022-01-07
    Sponsor Name:Helse Bergen HF, Haukeland University Hospital
    Full Title: PROSPECTIVE COMPARISON OF SIROLIMUS AGAINST CORTICOSTEROIDS IN TREATMENT OF PATIENTS WITH ACTIVE THYROID EYE DISEASE
    Medical condition: Thyroid Eye Disease (TED) in patients with Graves' Diease.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002547-27 Sponsor Protocol Number: OP/CD001 Start Date*: 2005-09-03
    Sponsor Name:University of Bristol
    Full Title: Combined Immunosuppression and Radiotherapy in Thyroid Eye Disease
    Medical condition: Thyroid Eye Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001492-37 Sponsor Protocol Number: Z-AMD Start Date*: 2019-11-01
    Sponsor Name:Oslo University Hospital
    Full Title: Zoledronic acid as adjuvant therapy in neovascular Age-related Macular Degeneration (The Z-AMD study): a randomized controlled pilot study
    Medical condition: Neovascular Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005999-36 Sponsor Protocol Number: HZNP-TEP-402 Start Date*: 2022-05-24
    Sponsor Name:Horizon Therapeutics U.S.A., Inc.
    Full Title: A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients with Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durat...
    Medical condition: Thyroid Eye Disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006794-37 Sponsor Protocol Number: VRDN-001-101 Start Date*: 2022-05-20
    Sponsor Name:Viridian Therapeutics, Inc.
    Full Title: A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and sub...
    Medical condition: Thyroid eye disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004853 10084358 Thyroid eye disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) IT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004436-34 Sponsor Protocol Number: CSOM230Y2201 Start Date*: 2017-02-06
    Sponsor Name:Novartis Pharma AG
    Full Title: A Multicenter, Placebo-Controlled, Single Dose Study in Acute Episodic and Chronic Cluster Headache to Evaluate the Safety and Efficacy of SOM230 subcutaneous (s.c.)
    Medical condition: Cluster headache
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10059133 Cluster headache PT
    20.0 10029205 - Nervous system disorders 10009698 Cluster headaches LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001317-16 Sponsor Protocol Number: TRAIN_2019 Start Date*: 2019-10-30
    Sponsor Name:ErasmusMC
    Full Title: The TRAIN study: TRAmetinib In Neurofibromatosis type 1 related symptomatic plexiform neurofibromas
    Medical condition: Adult patients (age >17 years) with (mosaic) NF1 with inoperable symptomatic plexiform neurofibromas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029267 Neurofibroma PT
    20.0 100000004850 10029270 Neurofibromatosis, type 1 (von Recklinghausen's disease) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003937-14 Sponsor Protocol Number: A-92-52030-164 Start Date*: 2005-09-27
    Sponsor Name:IPSEN PHARMA, S.A
    Full Title: A phase II, unicentre, randomized, double-blind, parallel and placebo-controlled, pilot study to evaluate the efficacy and safety of Somatuline Autogel (60 mg) in patients with active thyroid-assoc...
    Medical condition: Active thyroid-associated ophtalmopathy of moderate intensity.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-001074-30 Sponsor Protocol Number: N20MAT Start Date*: 2020-06-26
    Sponsor Name:Netherlands cancer institute (NKI) Antioni van Leeuwenhoek (AvL)
    Full Title: Neo-adjuvant nivolumab or nivolumab with ipilimumab in advanced cutaneous squamous cell carcinoma patients prior to standard of care surgery; the MATISSE trial
    Medical condition: Primary or recurrent stage III-IVA cutaneous squamous cell carcinoma of all body sites OR tage I-II cutaneous squamous cell carcinoma, only in the case of: • Presence of multifocal disease for wh...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041834 Squamous cell carcinoma of skin PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077314 Skin squamous cell carcinoma metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081136 Skin squamous cell carcinoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001611-24 Sponsor Protocol Number: CAIN457ADE16 Start Date*: 2021-07-26
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A two-year multi-center Phase 3 study to investigate the efficacy and safety of secukinumab in adult patients with active, moderate to severe thyroid eye disease (ORBIT), with a randomized, paralle...
    Medical condition: Active, moderate to severe thyroid eye disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10060742 Endocrine ophthalmopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023125-38 Sponsor Protocol Number: NLG-LBC05 Start Date*: 2011-01-21
    Sponsor Name:Nordic Lymphoma Group
    Full Title: Dose densified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk (aaIPI≥2) Diffuse Large B-Cell Lymphoma.
    Medical condition: Diffuse large B-cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012825 Diffuse large B-cell lymphoma stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012824 Diffuse large B-cell lymphoma stage II PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012826 Diffuse large B-cell lymphoma stage IV PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Temporarily Halted) FI (Completed) NO (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-004999-36 Sponsor Protocol Number: BCBe/04/FRO-CLU/001 Start Date*: 2006-11-06
    Sponsor Name:Berlin-Chemie AG
    Full Title: Effects of Frovatriptan as Prophylactic Treatment of Cluster Headache, a Multi-Center, Placebo Controlled, Randomized, Double-Blind Prospective Phase III Parallel-Group Trial Comparing Frovatriptan...
    Medical condition: Episodic cluster headache
    Disease: Version SOC Term Classification Code Term Level
    8.0 10009698 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019058-42 Sponsor Protocol Number: LITIO-SUM-FC-002 Start Date*: 2010-05-26
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
    Full Title: Safety of sumatriptan in combination with lithium for treatment of cluster headache, Pilot Study,Phase II
    Medical condition: Cluster Headache
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019232 Headaches cluster LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001056-35 Sponsor Protocol Number: TXA Start Date*: 2014-11-24
    Sponsor Name:IRCCS Istituto Giannina Gaslini
    Full Title: The Effectiveness and Population Pharmacokinetics and Pharmacogenomics of a Reduced Dose of Tranexamic Acid for Craniosynostosis Surgery: A multicenter study. The TXA Study.
    Medical condition: craniosynostosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10049889 Craniosynostosis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000248-91 Sponsor Protocol Number: BTACH2012 Start Date*: 2013-01-08
    Sponsor Name:Institutt for nevromedisin, NTNU
    Full Title: Endoscopic block of the sphenopalatine ganglion with botulinum toxin in intractable cluster headache. Safety issues.
    Medical condition: Pharmacological refractory cluster headache with durations of periods of attacks normally more than 2 months
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10009698 Cluster headaches LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 05 14:41:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA